A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

医学 止吐药 化疗引起恶心呕吐 恶心 奥氮平 呕吐 消炎药 安慰剂 化疗 干呕 养生 昂丹司琼 临床终点 化疗方案 麻醉 内科学 随机对照试验 精神科 精神分裂症(面向对象编程) 替代医学 病理
作者
Yuanyuan Zhao,Yunpeng Yang,Fangfang Gao,Chang-Lu Hu,Diansheng Zhong,Miaozhen Lu,Zhiping Yuan,Jianqing Zhao,Jidong Miao,Yán Li,Jie Zhu,Chunbin Wang,Jianjun Han,Yanqiu Zhao,Yan Huang,Li Zhang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:55: 101771-101771 被引量:23
标识
DOI:10.1016/j.eclinm.2022.101771
摘要

BackgroundEvidence supports prophylactic use of olanzapine for the treatment of chemotherapy-induced nausea and vomiting (CINV). However, most studies to date have focused on patients with single-day highly emetogenic chemotherapy (HEC). Currently, administration of antiemetic therapies for nausea and vomiting induced by multiday chemotherapy regimens remains a challenge. In this study, we evaluated the efficacy of olanzapine combined with triple antiemetic therapy for the prevention of CINV in patients receiving multiday chemotherapy.MethodsWe performed a randomized, double-blind, placebo-controlled phase 3 trial in 22 hospitals. Eligible patients were between 18 and 75 years old, were diagnosed with malignant solid tumors, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. All the study participants were scheduled to be treated with chemotherapy regimens containing 3-day cisplatin (3-day total dose ≥75 mg/m2). Randomization was computer generated and stratified by gender and chemotherapy treatment history. Allocation was done via an interactive web response system. Enrolled patients were randomly assigned 1:1 to receive either 5 mg olanzapine or placebo orally before bedtime for 5 days combined with intravenous fosaprepitant (150 mg) 1 h before the administration of cisplatin on day 1, ondansetron hydrochloride intravenously, and dexamethasone orally 30 min before cisplatin from days 1 to 3. Dexamethasone was also administered at the same time on days 4 and 5. The primary endpoint was the proportion of subjects with complete response (no vomiting and no rescue therapy) within the overall phase (days 1–8) after starting chemotherapy. Baseline plasma concentrations of P-substance and 5-HT were measured for exploratory analysis. This study was registered at ClinicalTrials.gov, number NCT04536558.FindingsBetween December 2020 and September 2021, 349 patients with malignant solid tumors were enrolled in the study, with 175 participants randomly assigned to receive olanzapine and 174 participants assigned to receive placebo. The proportion of patients who achieved a complete response in the overall phase was significantly higher in the olanzapine group than in the placebo group (69% vs. 58%, P = 0.031). A complete response benefit was observed in the olanzapine group versus the placebo group in almost all the subgroups. Four factors were considered significantly associated with complete response in multivariable analysis: treatment group, gender, baseline plasma concentration of 5-HT, and prior radiotherapy. All the reported adverse events associated with olanzapine administration were grades 1 and 2.InterpretationOlanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone was better than triple antiemetic therapy alone for patients receiving multiday chemotherapy regimens. Based on these results, the four-drug combination should be recommended as the best antiemetic regimen given to patients receiving multiday cisplatin-based chemotherapy and baseline plasma concentration of 5-HT may be used to identify individuals who are prone to CINV. However, all these findings need to be further validated in future studies.FundingJiangsu Hansoh Pharmaceutical Group Co., Ltd. provided research grant and study drugs for this investigator-initiated study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fufufu123完成签到 ,获得积分10
1秒前
开心的大娘完成签到,获得积分10
1秒前
www完成签到 ,获得积分10
3秒前
末末完成签到 ,获得积分10
13秒前
无为完成签到 ,获得积分10
14秒前
白嫖论文完成签到 ,获得积分10
16秒前
上官若男应助忧伤的步美采纳,获得10
19秒前
科研通AI2S应助科研通管家采纳,获得10
19秒前
22秒前
从心随缘完成签到 ,获得积分10
23秒前
花花发布了新的文献求助10
25秒前
牛奶面包完成签到 ,获得积分10
26秒前
27秒前
岁月如歌完成签到 ,获得积分0
27秒前
30秒前
Li完成签到,获得积分10
32秒前
张琨完成签到 ,获得积分10
32秒前
32秒前
sunnyqqz完成签到,获得积分10
35秒前
热情的乘风完成签到,获得积分20
35秒前
37秒前
霍凡白完成签到,获得积分10
38秒前
39秒前
Feng发布了新的文献求助20
40秒前
怕孤单的若颜完成签到 ,获得积分10
42秒前
43秒前
ruochenzu发布了新的文献求助10
46秒前
zhongu发布了新的文献求助10
50秒前
阳光彩虹小白马完成签到 ,获得积分10
50秒前
Feng完成签到,获得积分10
52秒前
花花完成签到,获得积分10
54秒前
57秒前
量子星尘发布了新的文献求助10
59秒前
杨一完成签到 ,获得积分10
1分钟前
猫猫头完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
忒寒碜完成签到,获得积分10
1分钟前
1分钟前
XU博士完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022